Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, discusses misconceptions around measurable residual disease (MRD). He emphasizes that an MRD negative status does not mean that there is no chance of relapse, and that MRD status depends strongly on the methods used to detect it. Finally, he discusses the importance of timing in extrapolating prognoses from MRD testing, pointing out that an MRD negative status has better prognostic implications when achieved earlier on in the treatment pathway.
MRD: common misconceptions and clinical considerations
